NASDAQ: AEZS;
TSX: AEZS
SIRION Logo 4.6.2020.png
PRIVATE COMPANY

11:00am ET

Jerome D. Jabbour
Chief Executive Officer

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.

Matinas_Logo.png
NYSE AMER: MTNB

11:30am ET

Mahesh Karande
President and Chief Executive Officer, Board Director

Omega Therapeutics™ is a genomic medicine company focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences.

Omega_Flagship-2019-10-15.png
PRIVATE COMPANY

1:00pm ET

celavie-logo.png
PRIVATE COMPANY
Sandy Solmon
Chief Executive Officer and President

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS).

1:30pm ET

Mark Tepper, Ph.D.
President and Chief Executive Officer

EuMentis Therapeutics Inc. is a privately held biopharmaceutical company focused on developing novel therapies to treat high value neurodevelopmental and neurodegenerative diseases.

EuMentis_Logo.png
PRIVATE COMPANY

2:00pm ET

Roelof Rongen
Co-Founder

DeMelle OncoPharma LLC is focused on developing pharmacological treatments for high-unmet need cancers, initially for pancreatic cancer.

DeMelle_Logo.png
PRIVATE COMPANY
© 2020 Virtual Investor Summit All rights reserved.

10:00am ET

Dr. Klaus Paulini
Executive Director; President and Chief Executive Officer;
Managing Director, Aeterna Zentaris GmbH

Aeterna Zentaris is a biotech company commercializing and developing therapeutic and diagnostic tests, particularly for growth hormone deficiency (GHD). Our lead product, macimorelin, is approved to diagnose adult GHD and being developed to diagnose pediatric GHD.

10:30am ET

Dieter Lingelbach
Chief Operating Officer, Executive Director

SIRION Biotech was founded in 2005 to lead the next generation of comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development.

Interactive Q&A Following Each Presentation